CO6801766A2 - 1,3-oxazinas como inhibidores de bace1 y/o bace2 - Google Patents
1,3-oxazinas como inhibidores de bace1 y/o bace2Info
- Publication number
- CO6801766A2 CO6801766A2 CO13258872A CO13258872A CO6801766A2 CO 6801766 A2 CO6801766 A2 CO 6801766A2 CO 13258872 A CO13258872 A CO 13258872A CO 13258872 A CO13258872 A CO 13258872A CO 6801766 A2 CO6801766 A2 CO 6801766A2
- Authority
- CO
- Colombia
- Prior art keywords
- bace2
- bace1
- oxazines
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11166208 | 2011-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6801766A2 true CO6801766A2 (es) | 2013-11-29 |
Family
ID=46125426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO13258872A CO6801766A2 (es) | 2011-05-16 | 2013-10-31 | 1,3-oxazinas como inhibidores de bace1 y/o bace2 |
Country Status (19)
Country | Link |
---|---|
US (1) | US8785436B2 (es) |
EP (1) | EP2709992A1 (es) |
JP (1) | JP2014513702A (es) |
KR (1) | KR20140041538A (es) |
CN (1) | CN103534243A (es) |
AU (1) | AU2012257834A1 (es) |
CA (1) | CA2832384A1 (es) |
CL (1) | CL2013003262A1 (es) |
CO (1) | CO6801766A2 (es) |
CR (1) | CR20130487A (es) |
EA (1) | EA201391670A1 (es) |
EC (1) | ECSP13013024A (es) |
IL (1) | IL229072A0 (es) |
MA (1) | MA35246B1 (es) |
MX (1) | MX2013013328A (es) |
PE (1) | PE20141005A1 (es) |
SG (1) | SG194848A1 (es) |
WO (1) | WO2012156284A1 (es) |
ZA (1) | ZA201308400B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2416603C9 (ru) | 2005-10-25 | 2012-06-20 | Сионоги Энд Ко., Лтд. | Производные аминодигидротиазина |
EP2147914B1 (en) | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
WO2008133273A1 (ja) * | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | アルツハイマー症治療用医薬組成物 |
KR101324426B1 (ko) | 2008-06-13 | 2013-10-31 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
US8703785B2 (en) * | 2008-10-22 | 2014-04-22 | Shionogi & Co., Ltd. | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity |
WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US8569310B2 (en) | 2009-10-08 | 2013-10-29 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use |
RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
CN103261199A (zh) | 2010-10-29 | 2013-08-21 | 盐野义制药株式会社 | 萘啶衍生物 |
EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
US9242943B2 (en) * | 2011-01-18 | 2016-01-26 | Siena Biotech S.P.A. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
US8399459B2 (en) * | 2011-02-02 | 2013-03-19 | Hoffmann-La Roche Inc. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
CN103608345A (zh) | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
WO2014010748A1 (en) * | 2012-07-10 | 2014-01-16 | Shionogi & Co., Ltd. | Cyclopropane derivative having bace1 inhibiting activity |
JP2016501827A (ja) * | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Bace1阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
BR112015016315A2 (pt) * | 2013-01-22 | 2017-07-11 | Hoffmann La Roche | fluoro-[1,3]oxazinas como inibidores de bace1 |
MX366855B (es) | 2013-03-01 | 2019-07-26 | Amgen Inc | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. |
MX2015011618A (es) | 2013-03-08 | 2015-12-17 | Amgen Inc | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso. |
KR102247765B1 (ko) | 2013-04-11 | 2021-05-06 | 에프. 호프만-라 로슈 아게 | Bace1 억제제 |
TWI639607B (zh) | 2013-06-18 | 2018-11-01 | 美國禮來大藥廠 | Bace抑制劑 |
WO2015132141A1 (en) * | 2014-03-03 | 2015-09-11 | F. Hoffmann-La Roche Ag | 1,3-oxazine-2-amine derivatives acting as bace inhibitors for the treatment of alzheimer's disease |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
WO2016001266A1 (en) | 2014-07-04 | 2016-01-07 | F. Hoffmann-La Roche Ag | Fluoro-[1,3]oxazines as bace1 inhibitors |
WO2016012384A1 (en) | 2014-07-22 | 2016-01-28 | F. Hoffmann-La Roche Ag | Trifluormethyloxazine amidines as bace1 inhibitors |
MX2017001794A (es) | 2014-08-08 | 2017-06-29 | Amgen Inc | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. |
CN105566179B (zh) * | 2014-10-14 | 2017-09-05 | 上海工程技术大学 | 一种制备手性α‑氟‑β‑氨基酸衍生物的方法 |
MX2017012188A (es) | 2015-03-20 | 2017-12-15 | Hoffmann La Roche | Inhibidores de beta-secretasa 1 (bace1). |
GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
TW201726651A (zh) | 2015-09-23 | 2017-08-01 | 健生藥品公司 | 2,3,4,5-四氫吡啶-6-胺衍生物 |
WO2017146187A1 (ja) * | 2016-02-25 | 2017-08-31 | 株式会社日本触媒 | オキソカーボン系化合物、樹脂組成物およびインク組成物 |
JP6616525B2 (ja) * | 2016-03-01 | 2019-12-04 | エフ.ホフマン−ラ ロシュ アーゲー | Bace1阻害剤 |
CN107304176A (zh) * | 2016-04-21 | 2017-10-31 | 上海工程技术大学 | α-芳基取代的α-氟代β-氨基酸类化合物及其制备方法 |
CA3047288A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Thiazine derivatives as beta-secretase inhibitors and methods of use |
MX2019007101A (es) | 2016-12-15 | 2019-12-16 | Amgen Inc | Derivados de oxazina como inhibidores de beta secretasa y metodos de uso. |
US11548903B2 (en) | 2016-12-15 | 2023-01-10 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
MA50007A (fr) | 2016-12-15 | 2021-04-07 | Amgen Inc | Dérivés de dioxyde de 1,4-thiazine et de dioxyde de 1,2,4-thiadiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
US10889581B2 (en) | 2016-12-15 | 2021-01-12 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
CN107892697B (zh) | 2016-12-26 | 2020-11-03 | 郑州泰基鸿诺医药股份有限公司 | 一种[1,3]噻嗪-2-胺类化合物及应用,药物组合物 |
EP3784674B1 (en) | 2018-04-27 | 2023-02-22 | Shionogi & Co., Ltd | Tetrahydropyranooxazine derivatives having selective bace1 inhibitory activity |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2520804A1 (en) | 2003-04-03 | 2004-10-28 | Merck & Co., Inc. | Biaryl substituted pyrazoles as sodium channel blockers |
RU2416603C9 (ru) | 2005-10-25 | 2012-06-20 | Сионоги Энд Ко., Лтд. | Производные аминодигидротиазина |
EP2032585B1 (de) | 2006-05-24 | 2014-07-23 | Boehringer Ingelheim International GmbH | Substituierte pteridine als therapeutika |
US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
EP2500344A4 (en) * | 2009-11-13 | 2013-05-01 | Shionogi & Co | AMINOTHIAZIN OR AMINOOXAZINE DERIVATIVES WITH AN AMINO TERMINATION |
US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
US8754075B2 (en) * | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
-
2012
- 2012-05-09 US US13/467,085 patent/US8785436B2/en not_active Expired - Fee Related
- 2012-05-11 EA EA201391670A patent/EA201391670A1/ru unknown
- 2012-05-11 CA CA2832384A patent/CA2832384A1/en not_active Abandoned
- 2012-05-11 SG SG2013082755A patent/SG194848A1/en unknown
- 2012-05-11 AU AU2012257834A patent/AU2012257834A1/en not_active Abandoned
- 2012-05-11 PE PE2013002497A patent/PE20141005A1/es not_active Application Discontinuation
- 2012-05-11 MX MX2013013328A patent/MX2013013328A/es not_active Application Discontinuation
- 2012-05-11 WO PCT/EP2012/058707 patent/WO2012156284A1/en active Application Filing
- 2012-05-11 CN CN201280023734.0A patent/CN103534243A/zh active Pending
- 2012-05-11 EP EP12722112.5A patent/EP2709992A1/en not_active Withdrawn
- 2012-05-11 JP JP2014510743A patent/JP2014513702A/ja active Pending
- 2012-05-11 KR KR1020137032852A patent/KR20140041538A/ko not_active Application Discontinuation
-
2013
- 2013-09-26 CR CR20130487A patent/CR20130487A/es unknown
- 2013-10-24 IL IL229072A patent/IL229072A0/en unknown
- 2013-10-31 CO CO13258872A patent/CO6801766A2/es not_active Application Discontinuation
- 2013-11-07 ZA ZA2013/08400A patent/ZA201308400B/en unknown
- 2013-11-14 CL CL2013003262A patent/CL2013003262A1/es unknown
- 2013-11-15 EC ECSP13013024 patent/ECSP13013024A/es unknown
- 2013-12-06 MA MA36536A patent/MA35246B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US8785436B2 (en) | 2014-07-22 |
MA35246B1 (fr) | 2014-07-03 |
ECSP13013024A (es) | 2014-01-31 |
CL2013003262A1 (es) | 2014-08-08 |
KR20140041538A (ko) | 2014-04-04 |
NZ616099A (en) | 2014-11-28 |
JP2014513702A (ja) | 2014-06-05 |
WO2012156284A1 (en) | 2012-11-22 |
CA2832384A1 (en) | 2012-11-22 |
US20120295900A1 (en) | 2012-11-22 |
ZA201308400B (en) | 2014-07-30 |
SG194848A1 (en) | 2013-12-30 |
EP2709992A1 (en) | 2014-03-26 |
IL229072A0 (en) | 2013-12-31 |
MX2013013328A (es) | 2014-01-08 |
AU2012257834A1 (en) | 2013-10-17 |
PE20141005A1 (es) | 2014-08-27 |
CR20130487A (es) | 2013-12-09 |
EA201391670A1 (ru) | 2014-03-31 |
CN103534243A (zh) | 2014-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6801766A2 (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
CO7071122A2 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
CO6811854A2 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
BR112013016360A2 (pt) | 1,4 oxazinas como inibidores de bace1 e/ou bace2 | |
CO6801773A2 (es) | Espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
BR112013014610A2 (pt) | 1,4 oxazinas como inibidores de bace1 e/ou bace2 | |
BR112013020019A2 (pt) | 1,4-oxazepinas como inibidores de bace1 e/ou bace2. | |
CO6890097A2 (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
CO6940411A2 (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
CL2014003228A1 (es) | Sintesis e intermediarios de compuestos heterocíclicos biologicamente activas. | |
CO6831983A2 (es) | Compuestos heterocíclicos como inhibidores de cinasas | |
AP4029A (en) | Inhibitors of beta-secretase | |
BR112014000022A2 (pt) | 1-3-tiazepinas ciclopropil-fundidas como inibidores de bace 1 e/ou bace 2 | |
BR112014003906A2 (pt) | compostos de piridazinona e seu uso como inibidores de daao | |
SMT201600211B (it) | Composti eterociclici e loro usi | |
IL236138A0 (en) | Difluoro-hexahydro-cyclopentaoxazinil and difluoro-hexahydro-benzooxazinil as BACE1 inhibitors | |
IL236963A0 (en) | beta-secretase inhibitors | |
DK2802537T3 (da) | Formaldehyd-frie lignin-amin-koaguleringsmidler | |
BR112015002652A2 (pt) | composições de poliolefina e artigos fabricados destas | |
BR112013005210A2 (pt) | compostos heterocíclicos como inibidores de dgat1 | |
ZA201309171B (en) | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors | |
FI20115638A0 (fi) | Menetelmä biopolttoaineen käsittelemiseksi sekä vastaava arinarakenne | |
ES2390324B8 (es) | Juego de brocas | |
TH1401007055A (th) | ไดฟลูออโร-เฮกซะไฮโดร-ไซโคลเพนตะออกซาซินิล และ ไดฟลูออโร-เฮกซะไฮโดร-เบนโซออกซาซินิลในรูปสารยับยั้ง bace1 | |
TH1401006514A (th) | วิธีการเตรียม 2-(2,3-ไดเมทิลเฟนิล)-1-โพรพานัลด้วยคลอโรอะซีโตน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |